MindMed | Jotup

MindMed to Participate in June Conferences

Retrieved on:

Dienstag, Mai 28, 2024

Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Medicine, MindMed

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following conferences:

MindMed to Participate at May Investor Conferences

Retrieved on:

Donnerstag, Mai 9, 2024

Biotechnology, Pharmaceutical, Health, Clinical Trials, MindMed, Conference, Medicine

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:
An audio webcast and replay of the fireside chat at the 2024 RBCCM Global Healthcare Conference will be accessible on MindMed’s Investor Relations website for up to 90 days following the event.

New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Retrieved on:

Donnerstag, Mai 9, 2024

Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay.

Key Points:

Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay.
(Graphic: Business Wire)
Three studies examined the impact of GAD on healthcare utilization and costs, workplace productivity, and healthcare quality of life (HC QOL).
“These studies clearly demonstrate that the burden of GAD on the US healthcare system, employers, and people living with GAD is enormous.
“We undertook these studies as part of our commitment to highlight the scale of the anxiety crisis and our mission to address this burden.

MindMed Reports First Quarter 2024 Financial Results and Business Updates

Retrieved on:

Mittwoch, Mai 8, 2024

Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, FDA, MindMed, ASD, Medicine, GAD, Week, Spectrum, BTD, ODT, Prevalence, Pharmaceutical industry

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.
For the quarter ended March 31, 2024, net cash used in operating activities was $16.6 million, compared to $13.3 million in the quarter ended March 31, 2023.
Net loss for the quarter ended March 31, 2024 was $54.4 million, compared to $24.8 million for the quarter ended March 31, 2023.
MindMed management will host a conference call at 4:30 PM EDT today to provide a corporate update and review the Company’s first quarter 2024 financial results.

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

Retrieved on:

Samstag, Mai 4, 2024

General Health, Health, Mental Health, APA, FDA, MindMed, Medicine, GAD, Week, Pharmaceutical industry

MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints.

Key Points:

MM120 demonstrated clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints.
The study was presented at the APA Annual Meeting, the largest psychiatry-focused scientific meeting in the world, in New York City being held May 4 – 8, 2024.
MM120 was administered as a single dose in a monitored clinical setting, with no additional therapeutic intervention, to demonstrate the medication’s effect.
In today’s presentation of the Phase 2b study with MM120, investigators presented results from the assessment of several additional secondary endpoints that were pre-specified.

MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update

Retrieved on:

Donnerstag, Mai 2, 2024

Biotechnology, Pharmaceutical, Health, MindMed, Webcast, Medicine

ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.

Key Points:

ET to provide a corporate update and review the Company’s results for the first quarter ended March 31, 2024.
Listeners can register for the webcast via this link .
A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/ , and archived for at least 30 days after the webcast.
Those who plan on participating are advised to join 15 minutes prior to the start time.

MindMed to Present at Upcoming May Medical Conferences

Retrieved on:

Donnerstag, April 25, 2024

Mental Health, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, APA, Congress, American Psychiatric Association, MindMed, Epidemiology, Medicine, GAD, Pharmacoeconomics, Lysergic acid diethylamide

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
American Psychiatric Association (APA) 2024 Congress, New York, NY
Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
Posters will be available on MindMed’s Company website following the conferences.

DATAcc by DiMe Launches Core Measures for Sleep

Retrieved on:

Mittwoch, April 24, 2024

BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) released a core set of digital measures and resources for sleep. Together, these will increase the availability of high-quality, standardized, and transparent sleep assessments in a natural environment and transform research and care to advance overall population health. The core digital measures set and resources were developed by a cross-disciplinary group of experts designed to maintain broad applicability across research, care, and multiple disease areas.

Key Points:

BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community ( DATAcc ) by the Digital Medicine Society ( DiMe ) released a core set of digital measures and resources for sleep .
Better sleep means better health, and disrupted sleep can indicate or cause chronic conditions ranging from primary sleep disorders to mental health conditions to Parkinson's Disease to Women's health to cardiac conditions and more.
"The core digital measures of sleep and accompanying resources now make it more accessible than ever before to incorporate sleep data into trials and care plans where sleep was previously inaccessible.
In addition to the core measures and over 15 new resources, the project team also added sleep digital measurement products to the Library of Digital Measurement Products.

MindMed to Present at Upcoming April Medical Conferences

Retrieved on:

Dienstag, April 2, 2024

Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Generalized anxiety disorder, Medicine, COVID, MindMed, Epidemiology

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences:

MindMed Announces Voluntary Delisting from Cboe Canada

Retrieved on:

Montag, April 1, 2024

Science, Neurology, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Medicine, MindMed, FAQ

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada.

Key Points:

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has elected to voluntarily delist its common shares from Cboe Canada, effective at the close of markets on April 10, 2024, and the notice of voluntary delisting has been accepted by Cboe Canada.
The board of directors of the Company has approved the voluntary delisting from Cboe Canada.
In accordance with the Cboe Canada Listing Manual, Cboe Canada does not require shareholder approval of the voluntary delisting of MindMed’s common shares, as an acceptable alternative market will exist for the common shares on the date of delisting.
MindMed will continue to be a reporting issuer under applicable securities laws in all provinces and territories of Canada following the delisting of the common shares from Cboe Canada.